Lyell Immunopharma (NASDAQ:LYEL) Stock Price Down 5.9% – What’s Next?

Lyell Immunopharma, Inc. (NASDAQ:LYEL) shares traded down 5.9% during mid-day trading on Tuesday . The stock traded as low as $9.02 and last traded at $9.10. 36,808 shares changed hands during trading, a decline of 49% from the average session volume of 72,562 shares. The stock had previously closed at $9.67.

Analyst Ratings Changes

A number of brokerages have commented on LYEL. Wall Street Zen raised shares of Lyell Immunopharma to a “hold” rating in a research note on Friday, June 6th. HC Wainwright restated a “neutral” rating and set a $10.00 target price on shares of Lyell Immunopharma in a report on Tuesday, June 24th.

Lyell Immunopharma Stock Down 5.9%

The firm’s 50 day simple moving average is $9.23 and its 200-day simple moving average is $10.59. The company has a market capitalization of $134.77 million, a PE ratio of -0.36 and a beta of -0.24.

Lyell Immunopharma (NASDAQ:LYEL) last posted its earnings results on Tuesday, May 13th. The company reported ($3.60) EPS for the quarter, topping analysts’ consensus estimates of ($3.80) by $0.20. The business had revenue of $0.01 million for the quarter. Lyell Immunopharma had a negative net margin of 514,649.22% and a negative return on equity of 73.66%. As a group, sell-side analysts anticipate that Lyell Immunopharma, Inc. will post -0.78 EPS for the current fiscal year.

Hedge Funds Weigh In On Lyell Immunopharma

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Lyell Immunopharma by 13.4% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 308,551 shares of the company’s stock valued at $197,000 after acquiring an additional 36,555 shares during the last quarter. Takeda Pharmaceutical Co. Ltd. purchased a new stake in Lyell Immunopharma during the fourth quarter valued at about $527,000. BNP Paribas Financial Markets purchased a new stake in Lyell Immunopharma during the fourth quarter valued at about $162,000. Johnson & Johnson purchased a new stake in Lyell Immunopharma during the fourth quarter valued at about $527,000. Finally, Geode Capital Management LLC lifted its stake in Lyell Immunopharma by 2.9% during the fourth quarter. Geode Capital Management LLC now owns 4,137,264 shares of the company’s stock valued at $2,648,000 after buying an additional 117,303 shares in the last quarter. Institutional investors own 66.05% of the company’s stock.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.